Onapgo

Overview

apomorphine

dopamine agonist

• CNS depression
• dopamine agonist
• hypotensive effects
• prolongs QT interval (known)

Contraindicated

• alosetron
Onapgo (apomorphine)

+

alosetron

1 interaction

Contraindicated

apomorphine + alosetron

contraindicated: combo may result in profound hypotension, loss of consciousness (mechanism unknown)

• cisapride
Onapgo (apomorphine)

+

cisapride

1 interaction

Contraindicated

apomorphine + cisapride

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dronedarone
Onapgo (apomorphine)

+

dronedarone

1 interaction

Contraindicated

apomorphine + dronedarone

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• granisetron
Onapgo (apomorphine)

+

granisetron

1 interaction

Contraindicated

apomorphine + granisetron

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound hypotension, loss of consciousness (additive effects)

• levoketoconazole
Onapgo (apomorphine)

+

levoketoconazole

1 interaction

Contraindicated

apomorphine + levoketoconazole

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ondansetron
Onapgo (apomorphine)

+

ondansetron

1 interaction

Contraindicated

apomorphine + ondansetron

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound hypotension, loss of consciousness (additive effects)

• palonosetron
Onapgo (apomorphine)

+

palonosetron

1 interaction

Contraindicated

apomorphine + palonosetron

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound hypotension, loss of consciousness (additive effects)

• pimozide
Onapgo (apomorphine)

+

pimozide

1 interaction

Contraindicated

apomorphine + pimozide

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• thioridazine
Onapgo (apomorphine)

+

thioridazine

1 interaction

Contraindicated

apomorphine + thioridazine

contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment; may decr. efficacy of both drugs (additive effects; antagonistic effects)

Avoid/Use Alternative

• adagrasib
Onapgo (apomorphine)

+

adagrasib

1 interaction

Avoid/Use Alternative

apomorphine + adagrasib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aldesleukin
Onapgo (apomorphine)

+

aldesleukin

1 interaction

Avoid/Use Alternative

apomorphine + aldesleukin

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe or life-threatening hypotension incl. orthostasis, syncope (additive effects)

• amiodarone
Onapgo (apomorphine)

+

amiodarone

1 interaction

Avoid/Use Alternative

apomorphine + amiodarone

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• amisulpride
Onapgo (apomorphine)

+

amisulpride

1 interaction

Avoid/Use Alternative

apomorphine + amisulpride

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• anagrelide
Onapgo (apomorphine)

+

anagrelide

1 interaction

Avoid/Use Alternative

apomorphine + anagrelide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apalutamide
Onapgo (apomorphine)

+

apalutamide

1 interaction

Avoid/Use Alternative

apomorphine + apalutamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• apomorphine
Onapgo (apomorphine)

+

apomorphine

1 interaction

Avoid/Use Alternative

apomorphine + apomorphine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• arsenic trioxide
Onapgo (apomorphine)

+

arsenic trioxide

1 interaction

Avoid/Use Alternative

apomorphine + arsenic trioxide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• artemether/lumefantrine
Onapgo (apomorphine)

+

artemether/ lumefantrine

1 interaction

Avoid/Use Alternative

apomorphine + artemether/ lumefantrine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• asenapine
Onapgo (apomorphine)

+

asenapine

1 interaction

Avoid/Use Alternative

apomorphine + asenapine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• azithromycin
Onapgo (apomorphine)

+

azithromycin

1 interaction

Avoid/Use Alternative

apomorphine + azithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bedaquiline
Onapgo (apomorphine)

+

bedaquiline

1 interaction

Avoid/Use Alternative

apomorphine + bedaquiline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• bromocriptine
Onapgo (apomorphine)

+

bromocriptine

1 interaction

Avoid/Use Alternative

apomorphine + bromocriptine

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• butalbital
Onapgo (apomorphine)

+

butalbital

1 interaction

Avoid/Use Alternative

apomorphine + butalbital

avoid combo: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• cabergoline
Onapgo (apomorphine)

+

cabergoline

1 interaction

Avoid/Use Alternative

apomorphine + cabergoline

avoid combo: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• cabozantinib
Onapgo (apomorphine)

+

cabozantinib

1 interaction

Avoid/Use Alternative

apomorphine + cabozantinib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ceritinib
Onapgo (apomorphine)

+

ceritinib

1 interaction

Avoid/Use Alternative

apomorphine + ceritinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chloroquine
Onapgo (apomorphine)

+

chloroquine

1 interaction

Avoid/Use Alternative

apomorphine + chloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• chlorpromazine
Onapgo (apomorphine)

+

chlorpromazine

1 interaction

Avoid/Use Alternative

apomorphine + chlorpromazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• citalopram
Onapgo (apomorphine)

+

citalopram

1 interaction

Avoid/Use Alternative

apomorphine + citalopram

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• clarithromycin
Onapgo (apomorphine)

+

clarithromycin

1 interaction

Avoid/Use Alternative

apomorphine + clarithromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clofazimine
Onapgo (apomorphine)

+

clofazimine

1 interaction

Avoid/Use Alternative

apomorphine + clofazimine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clonidine
Onapgo (apomorphine)

+

clonidine

1 interaction

Avoid/Use Alternative

apomorphine + clonidine

if ADHD use, avoid combo; otherwise, monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• clozapine
Onapgo (apomorphine)

+

clozapine

1 interaction

Avoid/Use Alternative

apomorphine + clozapine

use alternative or monitor BP, HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• codeine
Onapgo (apomorphine)

+

codeine

1 interaction

Avoid/Use Alternative

apomorphine + codeine

avoid combo if antitussive use; otherwise monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• crizotinib
Onapgo (apomorphine)

+

crizotinib

1 interaction

Avoid/Use Alternative

apomorphine + crizotinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• degarelix
Onapgo (apomorphine)

+

degarelix

1 interaction

Avoid/Use Alternative

apomorphine + degarelix

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• desflurane
Onapgo (apomorphine)

+

desflurane

1 interaction

Avoid/Use Alternative

apomorphine + desflurane

use alternative or monitor ECG, BP, resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS and resp. depression, psychomotor impairment (additive effects)

• desipramine
Onapgo (apomorphine)

+

desipramine

1 interaction

Avoid/Use Alternative

apomorphine + desipramine

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• dexmedetomidine
Onapgo (apomorphine)

+

dexmedetomidine

1 interaction

Avoid/Use Alternative

apomorphine + dexmedetomidine

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• dexmedetomidine injection
Onapgo (apomorphine)

+

dexmedetomidine injection

1 interaction

Avoid/Use Alternative

apomorphine + dexmedetomidine injection

use alternative or monitor ECG, BP, resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment, severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

• disopyramide
Onapgo (apomorphine)

+

disopyramide

1 interaction

Avoid/Use Alternative

apomorphine + disopyramide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• dofetilide
Onapgo (apomorphine)

+

dofetilide

1 interaction

Avoid/Use Alternative

apomorphine + dofetilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• domperidone
Onapgo (apomorphine)

+

domperidone

1 interaction

Avoid/Use Alternative

apomorphine + domperidone

use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• donepezil
Onapgo (apomorphine)

+

donepezil

1 interaction

Avoid/Use Alternative

apomorphine + donepezil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• doxylamine
Onapgo (apomorphine)

+

doxylamine

1 interaction

Avoid/Use Alternative

apomorphine + doxylamine

avoid combo if doxylamine use for pregnancy-related nausea/vomiting; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• droperidol
Onapgo (apomorphine)

+

droperidol

1 interaction

Avoid/Use Alternative

apomorphine + droperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• efavirenz
Onapgo (apomorphine)

+

efavirenz

1 interaction

Avoid/Use Alternative

apomorphine + efavirenz

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• encorafenib
Onapgo (apomorphine)

+

encorafenib

1 interaction

Avoid/Use Alternative

apomorphine + encorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• entrectinib
Onapgo (apomorphine)

+

entrectinib

1 interaction

Avoid/Use Alternative

apomorphine + entrectinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• ephedra
Onapgo (apomorphine)

+

ephedra

1 interaction

Avoid/Use Alternative

apomorphine + ephedra

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• epirubicin
Onapgo (apomorphine)

+

epirubicin

1 interaction

Avoid/Use Alternative

apomorphine + epirubicin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• eribulin
Onapgo (apomorphine)

+

eribulin

1 interaction

Avoid/Use Alternative

apomorphine + eribulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• erythromycin
Onapgo (apomorphine)

+

erythromycin

1 interaction

Avoid/Use Alternative

apomorphine + erythromycin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ethanol
Onapgo (apomorphine)

+

ethanol

1 interaction

Avoid/Use Alternative

apomorphine + ethanol

avoid combo: coingestion of oral alcohol w/ apomorphine may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• etrasimod
Onapgo (apomorphine)

+

etrasimod

1 interaction

Avoid/Use Alternative

apomorphine + etrasimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• fenoldopam
Onapgo (apomorphine)

+

fenoldopam

1 interaction

Avoid/Use Alternative

apomorphine + fenoldopam

avoid combo: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• fexinidazole
Onapgo (apomorphine)

+

fexinidazole

1 interaction

Avoid/Use Alternative

apomorphine + fexinidazole

if possible, do not initiate fexinidazole until 5 half-lives after apomorphine D/C; use alternative or monitor ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flecainide
Onapgo (apomorphine)

+

flecainide

1 interaction

Avoid/Use Alternative

apomorphine + flecainide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluorouracil
Onapgo (apomorphine)

+

fluorouracil

1 interaction

Avoid/Use Alternative

apomorphine + fluorouracil

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fluoxetine
Onapgo (apomorphine)

+

fluoxetine

1 interaction

Avoid/Use Alternative

apomorphine + fluoxetine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• fluphenazine
Onapgo (apomorphine)

+

fluphenazine

1 interaction

Avoid/Use Alternative

apomorphine + fluphenazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• foscarnet
Onapgo (apomorphine)

+

foscarnet

1 interaction

Avoid/Use Alternative

apomorphine + foscarnet

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepotidacin
Onapgo (apomorphine)

+

gepotidacin

1 interaction

Avoid/Use Alternative

apomorphine + gepotidacin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gilteritinib
Onapgo (apomorphine)

+

gilteritinib

1 interaction

Avoid/Use Alternative

apomorphine + gilteritinib

use alternative or monitor ECG, electrolytes, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• givinostat
Onapgo (apomorphine)

+

givinostat

1 interaction

Avoid/Use Alternative

apomorphine + givinostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• glasdegib
Onapgo (apomorphine)

+

glasdegib

1 interaction

Avoid/Use Alternative

apomorphine + glasdegib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• goserelin
Onapgo (apomorphine)

+

goserelin

1 interaction

Avoid/Use Alternative

apomorphine + goserelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• grapefruit
Onapgo (apomorphine)

+

grapefruit

1 interaction

Avoid/Use Alternative

apomorphine + grapefruit

use alternative or monitor ECG w/ large amounts of grapefruit (>1L juice): combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• haloperidol
Onapgo (apomorphine)

+

haloperidol

1 interaction

Avoid/Use Alternative

apomorphine + haloperidol

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• histrelin
Onapgo (apomorphine)

+

histrelin

1 interaction

Avoid/Use Alternative

apomorphine + histrelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• hydrocodone
Onapgo (apomorphine)

+

hydrocodone

1 interaction

Avoid/Use Alternative

apomorphine + hydrocodone

avoid combo if antitussive use; otherwise, monitor resp. rate, BP, ECG, electrolytes, especially if hydrocodone ER doses >160 mg/day; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• hydroxychloroquine
Onapgo (apomorphine)

+

hydroxychloroquine

1 interaction

Avoid/Use Alternative

apomorphine + hydroxychloroquine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• hydroxyzine
Onapgo (apomorphine)

+

hydroxyzine

1 interaction

Avoid/Use Alternative

apomorphine + hydroxyzine

use alternative or monitor ECG; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• ibutilide
Onapgo (apomorphine)

+

ibutilide

1 interaction

Avoid/Use Alternative

apomorphine + ibutilide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• iloperidone
Onapgo (apomorphine)

+

iloperidone

1 interaction

Avoid/Use Alternative

apomorphine + iloperidone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• inotuzumab ozogamicin
Onapgo (apomorphine)

+

inotuzumab ozogamicin

1 interaction

Avoid/Use Alternative

apomorphine + inotuzumab ozogamicin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• isocarboxazid
Onapgo (apomorphine)

+

isocarboxazid

1 interaction

Avoid/Use Alternative

apomorphine + isocarboxazid

use alternative during and x10 days after isocarboxazid use: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• isoflurane
Onapgo (apomorphine)

+

isoflurane

1 interaction

Avoid/Use Alternative

apomorphine + isoflurane

use alternative or monitor BP, ECG, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), profound CNS and resp. depression, psychomotor impairment (additive effects)

• ivabradine
Onapgo (apomorphine)

+

ivabradine

1 interaction

Avoid/Use Alternative

apomorphine + ivabradine

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• ivosidenib
Onapgo (apomorphine)

+

ivosidenib

1 interaction

Avoid/Use Alternative

apomorphine + ivosidenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• kava
Onapgo (apomorphine)

+

kava

1 interaction

Avoid/Use Alternative

apomorphine + kava

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment; may decr. apomorphine efficacy (additive effects; antagonistic effects)

• kratom
Onapgo (apomorphine)

+

kratom

1 interaction

Avoid/Use Alternative

apomorphine + kratom

use alternative or monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• lefamulin
Onapgo (apomorphine)

+

lefamulin

1 interaction

Avoid/Use Alternative

apomorphine + lefamulin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• leuprolide
Onapgo (apomorphine)

+

leuprolide

1 interaction

Avoid/Use Alternative

apomorphine + leuprolide

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• levofloxacin
Onapgo (apomorphine)

+

levofloxacin

1 interaction

Avoid/Use Alternative

apomorphine + levofloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lofexidine
Onapgo (apomorphine)

+

lofexidine

1 interaction

Avoid/Use Alternative

apomorphine + lofexidine

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• lonafarnib
Onapgo (apomorphine)

+

lonafarnib

1 interaction

Avoid/Use Alternative

apomorphine + lonafarnib

use alternative or monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• loperamide
Onapgo (apomorphine)

+

loperamide

1 interaction

Avoid/Use Alternative

apomorphine + loperamide

use alternative or monitor ECG, esp. if loperamide dose >16mg/day: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lopinavir/ritonavir
Onapgo (apomorphine)

+

lopinavir/ ritonavir

1 interaction

Avoid/Use Alternative

apomorphine + lopinavir/ ritonavir

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• loxapine
Onapgo (apomorphine)

+

loxapine

1 interaction

Avoid/Use Alternative

apomorphine + loxapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• lumateperone
Onapgo (apomorphine)

+

lumateperone

1 interaction

Avoid/Use Alternative

apomorphine + lumateperone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• lurasidone
Onapgo (apomorphine)

+

lurasidone

1 interaction

Avoid/Use Alternative

apomorphine + lurasidone

use alternative or monitor ECG, BP; consider lowest lurasidone start dose, titrate slowly: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• macimorelin
Onapgo (apomorphine)

+

macimorelin

1 interaction

Avoid/Use Alternative

apomorphine + macimorelin

avoid combo, allowing sufficient washout time before diagnostic test: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• metaxalone
Onapgo (apomorphine)

+

metaxalone

1 interaction

Avoid/Use Alternative

apomorphine + metaxalone

use alternative or monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• methadone
Onapgo (apomorphine)

+

methadone

1 interaction

Avoid/Use Alternative

apomorphine + methadone

use alternative or monitor resp. rate, ECG, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• metoclopramide
Onapgo (apomorphine)

+

metoclopramide

1 interaction

Avoid/Use Alternative

apomorphine + metoclopramide

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• midazolam
Onapgo (apomorphine)

+

midazolam

1 interaction

Avoid/Use Alternative

apomorphine + midazolam

use alternative or monitor resp. rate, BP; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• mifepristone
Onapgo (apomorphine)

+

mifepristone

1 interaction

Avoid/Use Alternative

apomorphine + mifepristone

use alternative or monitor ECG if daily mifepristone use: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mobocertinib
Onapgo (apomorphine)

+

mobocertinib

1 interaction

Avoid/Use Alternative

apomorphine + mobocertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• molindone
Onapgo (apomorphine)

+

molindone

1 interaction

Avoid/Use Alternative

apomorphine + molindone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• moxifloxacin
Onapgo (apomorphine)

+

moxifloxacin

1 interaction

Avoid/Use Alternative

apomorphine + moxifloxacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• nilotinib
Onapgo (apomorphine)

+

nilotinib

1 interaction

Avoid/Use Alternative

apomorphine + nilotinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olanzapine
Onapgo (apomorphine)

+

olanzapine

1 interaction

Avoid/Use Alternative

apomorphine + olanzapine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• oliceridine
Onapgo (apomorphine)

+

oliceridine

1 interaction

Avoid/Use Alternative

apomorphine + oliceridine

use alternative or monitor resp. rate, ECG, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• osimertinib
Onapgo (apomorphine)

+

osimertinib

1 interaction

Avoid/Use Alternative

apomorphine + osimertinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxaliplatin
Onapgo (apomorphine)

+

oxaliplatin

1 interaction

Avoid/Use Alternative

apomorphine + oxaliplatin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxybate
Onapgo (apomorphine)

+

oxybate

1 interaction

Avoid/Use Alternative

apomorphine + oxybate

use alternative or monitor resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, hypotension, syncope (additive effects)

• ozanimod
Onapgo (apomorphine)

+

ozanimod

1 interaction

Avoid/Use Alternative

apomorphine + ozanimod

consider alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pacritinib
Onapgo (apomorphine)

+

pacritinib

1 interaction

Avoid/Use Alternative

apomorphine + pacritinib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• paliperidone
Onapgo (apomorphine)

+

paliperidone

1 interaction

Avoid/Use Alternative

apomorphine + paliperidone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• panobinostat
Onapgo (apomorphine)

+

panobinostat

1 interaction

Avoid/Use Alternative

apomorphine + panobinostat

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pasireotide
Onapgo (apomorphine)

+

pasireotide

1 interaction

Avoid/Use Alternative

apomorphine + pasireotide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pazopanib
Onapgo (apomorphine)

+

pazopanib

1 interaction

Avoid/Use Alternative

apomorphine + pazopanib

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pentamidine
Onapgo (apomorphine)

+

pentamidine

1 interaction

Avoid/Use Alternative

apomorphine + pentamidine

use alternative or monitor ECG, BP; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

• perphenazine
Onapgo (apomorphine)

+

perphenazine

1 interaction

Avoid/Use Alternative

apomorphine + perphenazine

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• phenelzine
Onapgo (apomorphine)

+

phenelzine

1 interaction

Avoid/Use Alternative

apomorphine + phenelzine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• phenobarbital
Onapgo (apomorphine)

+

phenobarbital

1 interaction

Avoid/Use Alternative

apomorphine + phenobarbital

avoid combo if neonatal seizure use; otherwise, monitor BP, resp. rate, ECG: combo may incr. risk of CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• pimavanserin
Onapgo (apomorphine)

+

pimavanserin

1 interaction

Avoid/Use Alternative

apomorphine + pimavanserin

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pitolisant
Onapgo (apomorphine)

+

pitolisant

1 interaction

Avoid/Use Alternative

apomorphine + pitolisant

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ponesimod
Onapgo (apomorphine)

+

ponesimod

1 interaction

Avoid/Use Alternative

apomorphine + ponesimod

use alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• pramipexole
Onapgo (apomorphine)

+

pramipexole

1 interaction

Avoid/Use Alternative

apomorphine + pramipexole

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• procainamide
Onapgo (apomorphine)

+

procainamide

1 interaction

Avoid/Use Alternative

apomorphine + procainamide

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• prochlorperazine
Onapgo (apomorphine)

+

prochlorperazine

1 interaction

Avoid/Use Alternative

apomorphine + prochlorperazine

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• promethazine
Onapgo (apomorphine)

+

promethazine

1 interaction

Avoid/Use Alternative

apomorphine + promethazine

avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• propafenone
Onapgo (apomorphine)

+

propafenone

1 interaction

Avoid/Use Alternative

apomorphine + propafenone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• quetiapine
Onapgo (apomorphine)

+

quetiapine

1 interaction

Avoid/Use Alternative

apomorphine + quetiapine

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• quinidine (antiarrhythmic)
Onapgo (apomorphine)

+

quinidine (antiarrhythmic)

1 interaction

Avoid/Use Alternative

apomorphine + quinidine (antiarrhythmic)

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinidine (CYP2D6 inhibitor)
Onapgo (apomorphine)

+

quinidine (CYP2D6 inhibitor)

1 interaction

Avoid/Use Alternative

apomorphine + quinidine (CYP2D6 inhibitor)

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quinine
Onapgo (apomorphine)

+

quinine

1 interaction

Avoid/Use Alternative

apomorphine + quinine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• quizartinib
Onapgo (apomorphine)

+

quizartinib

1 interaction

Avoid/Use Alternative

apomorphine + quizartinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• revumenib
Onapgo (apomorphine)

+

revumenib

1 interaction

Avoid/Use Alternative

apomorphine + revumenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ribociclib
Onapgo (apomorphine)

+

ribociclib

1 interaction

Avoid/Use Alternative

apomorphine + ribociclib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rilpivirine
Onapgo (apomorphine)

+

rilpivirine

1 interaction

Avoid/Use Alternative

apomorphine + rilpivirine

consider alternative or monitor ECG; risk may be lower w/ IM rilpivirine: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• risperidone
Onapgo (apomorphine)

+

risperidone

1 interaction

Avoid/Use Alternative

apomorphine + risperidone

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• romidepsin
Onapgo (apomorphine)

+

romidepsin

1 interaction

Avoid/Use Alternative

apomorphine + romidepsin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ropeginterferon alfa-2b
Onapgo (apomorphine)

+

ropeginterferon alfa-2b

1 interaction

Avoid/Use Alternative

apomorphine + ropeginterferon alfa-2b

use alternative: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ropinirole
Onapgo (apomorphine)

+

ropinirole

1 interaction

Avoid/Use Alternative

apomorphine + ropinirole

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• rotigotine transdermal
Onapgo (apomorphine)

+

rotigotine transdermal

1 interaction

Avoid/Use Alternative

apomorphine + rotigotine transdermal

avoid combo: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension (incl. orthostasis, syncope), other adverse effects (additive effects, duplicate tx)

• rucaparib
Onapgo (apomorphine)

+

rucaparib

1 interaction

Avoid/Use Alternative

apomorphine + rucaparib

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selpercatinib
Onapgo (apomorphine)

+

selpercatinib

1 interaction

Avoid/Use Alternative

apomorphine + selpercatinib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sertraline
Onapgo (apomorphine)

+

sertraline

1 interaction

Avoid/Use Alternative

apomorphine + sertraline

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• sevoflurane
Onapgo (apomorphine)

+

sevoflurane

1 interaction

Avoid/Use Alternative

apomorphine + sevoflurane

use alternative or monitor ECG, BP, resp. rate: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS and resp. depression, psychomotor impairment (additive effects)

• siponimod
Onapgo (apomorphine)

+

siponimod

1 interaction

Avoid/Use Alternative

apomorphine + siponimod

consider alternative or monitor HR, ECG: combo may incr. risk of bradycardia, AV block, QT prolongation, cardiac arrhythmias (additive effects)

• solifenacin
Onapgo (apomorphine)

+

solifenacin

1 interaction

Avoid/Use Alternative

apomorphine + solifenacin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• sorafenib
Onapgo (apomorphine)

+

sorafenib

1 interaction

Avoid/Use Alternative

apomorphine + sorafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sotalol
Onapgo (apomorphine)

+

sotalol

1 interaction

Avoid/Use Alternative

apomorphine + sotalol

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• telavancin
Onapgo (apomorphine)

+

telavancin

1 interaction

Avoid/Use Alternative

apomorphine + telavancin

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tetrabenazine
Onapgo (apomorphine)

+

tetrabenazine

1 interaction

Avoid/Use Alternative

apomorphine + tetrabenazine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• thalidomide
Onapgo (apomorphine)

+

thalidomide

1 interaction

Avoid/Use Alternative

apomorphine + thalidomide

use alternative or monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• thiothixene
Onapgo (apomorphine)

+

thiothixene

1 interaction

Avoid/Use Alternative

apomorphine + thiothixene

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• toremifene
Onapgo (apomorphine)

+

toremifene

1 interaction

Avoid/Use Alternative

apomorphine + toremifene

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tramadol
Onapgo (apomorphine)

+

tramadol

1 interaction

Avoid/Use Alternative

apomorphine + tramadol

use alternative or monitor resp. rate, ECG, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• tranylcypromine
Onapgo (apomorphine)

+

tranylcypromine

1 interaction

Avoid/Use Alternative

apomorphine + tranylcypromine

use alternative or monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• trazodone
Onapgo (apomorphine)

+

trazodone

1 interaction

Avoid/Use Alternative

apomorphine + trazodone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• triclabendazole
Onapgo (apomorphine)

+

triclabendazole

1 interaction

Avoid/Use Alternative

apomorphine + triclabendazole

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• trifluoperazine
Onapgo (apomorphine)

+

trifluoperazine

1 interaction

Avoid/Use Alternative

apomorphine + trifluoperazine

use alternative or monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• trifluridine
Onapgo (apomorphine)

+

trifluridine

1 interaction

Avoid/Use Alternative

apomorphine + trifluridine

use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• triptorelin
Onapgo (apomorphine)

+

triptorelin

1 interaction

Avoid/Use Alternative

apomorphine + triptorelin

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation prolongs QT)

• vandetanib
Onapgo (apomorphine)

+

vandetanib

1 interaction

Avoid/Use Alternative

apomorphine + vandetanib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vemurafenib
Onapgo (apomorphine)

+

vemurafenib

1 interaction

Avoid/Use Alternative

apomorphine + vemurafenib

use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• ziprasidone
Onapgo (apomorphine)

+

ziprasidone

1 interaction

Avoid/Use Alternative

apomorphine + ziprasidone

use alternative or monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment; may decr. efficacy of both drugs (additive effects; antagonistic effects)

• zuranolone
Onapgo (apomorphine)

+

zuranolone

1 interaction

Avoid/Use Alternative

apomorphine + zuranolone

use alternative or consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

Monitor/Modify Tx

• acebutolol
Onapgo (apomorphine)

+

acebutolol

1 interaction

Monitor/Modify Tx

apomorphine + acebutolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• albuterol
Onapgo (apomorphine)

+

albuterol

1 interaction

Monitor/Modify Tx

apomorphine + albuterol

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• albuterol inhaled
Onapgo (apomorphine)

+

albuterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + albuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• alfentanil
Onapgo (apomorphine)

+

alfentanil

1 interaction

Monitor/Modify Tx

apomorphine + alfentanil

monitor BP, resp. rate; decr. dose of one or both drugs: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• alfuzosin
Onapgo (apomorphine)

+

alfuzosin

1 interaction

Monitor/Modify Tx

apomorphine + alfuzosin

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• aliskiren
Onapgo (apomorphine)

+

aliskiren

1 interaction

Monitor/Modify Tx

apomorphine + aliskiren

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• alprazolam
Onapgo (apomorphine)

+

alprazolam

1 interaction

Monitor/Modify Tx

apomorphine + alprazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• amantadine
Onapgo (apomorphine)

+

amantadine

1 interaction

Monitor/Modify Tx

apomorphine + amantadine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• amifostine
Onapgo (apomorphine)

+

amifostine

1 interaction

Monitor/Modify Tx

apomorphine + amifostine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• amiloride
Onapgo (apomorphine)

+

amiloride

1 interaction

Monitor/Modify Tx

apomorphine + amiloride

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• amitriptyline
Onapgo (apomorphine)

+

amitriptyline

1 interaction

Monitor/Modify Tx

apomorphine + amitriptyline

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• amlodipine
Onapgo (apomorphine)

+

amlodipine

1 interaction

Monitor/Modify Tx

apomorphine + amlodipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• amoxapine
Onapgo (apomorphine)

+

amoxapine

1 interaction

Monitor/Modify Tx

apomorphine + amoxapine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• apraclonidine ophthalmic
Onapgo (apomorphine)

+

apraclonidine ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + apraclonidine ophthalmic

monitor BP if apraclonidine IOP adjunct use; postop use OK: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• aprocitentan
Onapgo (apomorphine)

+

aprocitentan

1 interaction

Monitor/Modify Tx

apomorphine + aprocitentan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• arformoterol inhaled
Onapgo (apomorphine)

+

arformoterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + arformoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• aripiprazole bimonthly injection
Onapgo (apomorphine)

+

aripiprazole bimonthly injection

1 interaction

Monitor/Modify Tx

apomorphine + aripiprazole bimonthly injection

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• aripiprazole lauroxil
Onapgo (apomorphine)

+

aripiprazole lauroxil

1 interaction

Monitor/Modify Tx

apomorphine + aripiprazole lauroxil

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• aripiprazole monthly injection
Onapgo (apomorphine)

+

aripiprazole monthly injection

1 interaction

Monitor/Modify Tx

apomorphine + aripiprazole monthly injection

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• aripiprazole oral
Onapgo (apomorphine)

+

aripiprazole oral

1 interaction

Monitor/Modify Tx

apomorphine + aripiprazole oral

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• articaine
Onapgo (apomorphine)

+

articaine

1 interaction

Monitor/Modify Tx

apomorphine + articaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• asciminib
Onapgo (apomorphine)

+

asciminib

1 interaction

Monitor/Modify Tx

apomorphine + asciminib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• atenolol
Onapgo (apomorphine)

+

atenolol

1 interaction

Monitor/Modify Tx

apomorphine + atenolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• avanafil
Onapgo (apomorphine)

+

avanafil

1 interaction

Monitor/Modify Tx

apomorphine + avanafil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• azilsartan medoxomil
Onapgo (apomorphine)

+

azilsartan medoxomil

1 interaction

Monitor/Modify Tx

apomorphine + azilsartan medoxomil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• baclofen intrathecal
Onapgo (apomorphine)

+

baclofen intrathecal

1 interaction

Monitor/Modify Tx

apomorphine + baclofen intrathecal

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• benazepril
Onapgo (apomorphine)

+

benazepril

1 interaction

Monitor/Modify Tx

apomorphine + benazepril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• berberine
Onapgo (apomorphine)

+

berberine

1 interaction

Monitor/Modify Tx

apomorphine + berberine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• berotralstat
Onapgo (apomorphine)

+

berotralstat

1 interaction

Monitor/Modify Tx

apomorphine + berotralstat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• betaxolol
Onapgo (apomorphine)

+

betaxolol

1 interaction

Monitor/Modify Tx

apomorphine + betaxolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• betaxolol ophthalmic
Onapgo (apomorphine)

+

betaxolol ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + betaxolol ophthalmic

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• bethanechol
Onapgo (apomorphine)

+

bethanechol

1 interaction

Monitor/Modify Tx

apomorphine + bethanechol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• bexagliflozin
Onapgo (apomorphine)

+

bexagliflozin

1 interaction

Monitor/Modify Tx

apomorphine + bexagliflozin

monitor BP: combo may incr. risk of hypotension, incl. orthostasis, syncope (additive effects)

• bisoprolol
Onapgo (apomorphine)

+

bisoprolol

1 interaction

Monitor/Modify Tx

apomorphine + bisoprolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• bortezomib
Onapgo (apomorphine)

+

bortezomib

1 interaction

Monitor/Modify Tx

apomorphine + bortezomib

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• brexpiprazole
Onapgo (apomorphine)

+

brexpiprazole

1 interaction

Monitor/Modify Tx

apomorphine + brexpiprazole

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• brimonidine ophthalmic
Onapgo (apomorphine)

+

brimonidine ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + brimonidine ophthalmic

monitor BP if elevated IOP use; OTC ocular redness use OK: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• brimonidine topical
Onapgo (apomorphine)

+

brimonidine topical

1 interaction

Monitor/Modify Tx

apomorphine + brimonidine topical

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• bumetanide
Onapgo (apomorphine)

+

bumetanide

1 interaction

Monitor/Modify Tx

apomorphine + bumetanide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• bupivacaine
Onapgo (apomorphine)

+

bupivacaine

1 interaction

Monitor/Modify Tx

apomorphine + bupivacaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• bupivacaine liposomal
Onapgo (apomorphine)

+

bupivacaine liposomal

1 interaction

Monitor/Modify Tx

apomorphine + bupivacaine liposomal

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• buprenorphine
Onapgo (apomorphine)

+

buprenorphine

1 interaction

Monitor/Modify Tx

apomorphine + buprenorphine

monitor ECG, resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• butorphanol
Onapgo (apomorphine)

+

butorphanol

1 interaction

Monitor/Modify Tx

apomorphine + butorphanol

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• canagliflozin
Onapgo (apomorphine)

+

canagliflozin

1 interaction

Monitor/Modify Tx

apomorphine + canagliflozin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• candesartan cilexetil
Onapgo (apomorphine)

+

candesartan cilexetil

1 interaction

Monitor/Modify Tx

apomorphine + candesartan cilexetil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• cannabis
Onapgo (apomorphine)

+

cannabis

1 interaction

Monitor/Modify Tx

apomorphine + cannabis

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• captopril
Onapgo (apomorphine)

+

captopril

1 interaction

Monitor/Modify Tx

apomorphine + captopril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• carbamazepine
Onapgo (apomorphine)

+

carbamazepine

1 interaction

Monitor/Modify Tx

apomorphine + carbamazepine

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, hypotension, incl. syncope (additive effects)

• cariprazine
Onapgo (apomorphine)

+

cariprazine

1 interaction

Monitor/Modify Tx

apomorphine + cariprazine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• carteolol ophthalmic
Onapgo (apomorphine)

+

carteolol ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + carteolol ophthalmic

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• carvedilol
Onapgo (apomorphine)

+

carvedilol

1 interaction

Monitor/Modify Tx

apomorphine + carvedilol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• chlordiazepoxide
Onapgo (apomorphine)

+

chlordiazepoxide

1 interaction

Monitor/Modify Tx

apomorphine + chlordiazepoxide

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• chloroprocaine
Onapgo (apomorphine)

+

chloroprocaine

1 interaction

Monitor/Modify Tx

apomorphine + chloroprocaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• chlorothiazide
Onapgo (apomorphine)

+

chlorothiazide

1 interaction

Monitor/Modify Tx

apomorphine + chlorothiazide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• chlorthalidone
Onapgo (apomorphine)

+

chlorthalidone

1 interaction

Monitor/Modify Tx

apomorphine + chlorthalidone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• cilostazol
Onapgo (apomorphine)

+

cilostazol

1 interaction

Monitor/Modify Tx

apomorphine + cilostazol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ciprofloxacin
Onapgo (apomorphine)

+

ciprofloxacin

1 interaction

Monitor/Modify Tx

apomorphine + ciprofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• clevidipine
Onapgo (apomorphine)

+

clevidipine

1 interaction

Monitor/Modify Tx

apomorphine + clevidipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• clobazam
Onapgo (apomorphine)

+

clobazam

1 interaction

Monitor/Modify Tx

apomorphine + clobazam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clofarabine
Onapgo (apomorphine)

+

clofarabine

1 interaction

Monitor/Modify Tx

apomorphine + clofarabine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• clomipramine
Onapgo (apomorphine)

+

clomipramine

1 interaction

Monitor/Modify Tx

apomorphine + clomipramine

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• clonazepam
Onapgo (apomorphine)

+

clonazepam

1 interaction

Monitor/Modify Tx

apomorphine + clonazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• clorazepate
Onapgo (apomorphine)

+

clorazepate

1 interaction

Monitor/Modify Tx

apomorphine + clorazepate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• coenzyme Q-10
Onapgo (apomorphine)

+

coenzyme Q-10

1 interaction

Monitor/Modify Tx

apomorphine + coenzyme Q-10

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• dapagliflozin
Onapgo (apomorphine)

+

dapagliflozin

1 interaction

Monitor/Modify Tx

apomorphine + dapagliflozin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• daridorexant
Onapgo (apomorphine)

+

daridorexant

1 interaction

Monitor/Modify Tx

apomorphine + daridorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• dasatinib
Onapgo (apomorphine)

+

dasatinib

1 interaction

Monitor/Modify Tx

apomorphine + dasatinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• denileukin diftitox
Onapgo (apomorphine)

+

denileukin diftitox

1 interaction

Monitor/Modify Tx

apomorphine + denileukin diftitox

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• deutetrabenazine
Onapgo (apomorphine)

+

deutetrabenazine

1 interaction

Monitor/Modify Tx

apomorphine + deutetrabenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• diazepam
Onapgo (apomorphine)

+

diazepam

1 interaction

Monitor/Modify Tx

apomorphine + diazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• dihydrocodeine
Onapgo (apomorphine)

+

dihydrocodeine

1 interaction

Monitor/Modify Tx

apomorphine + dihydrocodeine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• diltiazem
Onapgo (apomorphine)

+

diltiazem

1 interaction

Monitor/Modify Tx

apomorphine + diltiazem

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• dinutuximab
Onapgo (apomorphine)

+

dinutuximab

1 interaction

Monitor/Modify Tx

apomorphine + dinutuximab

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• dipyridamole
Onapgo (apomorphine)

+

dipyridamole

1 interaction

Monitor/Modify Tx

apomorphine + dipyridamole

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• doxazosin
Onapgo (apomorphine)

+

doxazosin

1 interaction

Monitor/Modify Tx

apomorphine + doxazosin

monitor BP, especially during doxazosin initiation/titration: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• doxepin
Onapgo (apomorphine)

+

doxepin

1 interaction

Monitor/Modify Tx

apomorphine + doxepin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• dronabinol
Onapgo (apomorphine)

+

dronabinol

1 interaction

Monitor/Modify Tx

apomorphine + dronabinol

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• duloxetine
Onapgo (apomorphine)

+

duloxetine

1 interaction

Monitor/Modify Tx

apomorphine + duloxetine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• eliglustat
Onapgo (apomorphine)

+

eliglustat

1 interaction

Monitor/Modify Tx

apomorphine + eliglustat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• empagliflozin
Onapgo (apomorphine)

+

empagliflozin

1 interaction

Monitor/Modify Tx

apomorphine + empagliflozin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• enalapril
Onapgo (apomorphine)

+

enalapril

1 interaction

Monitor/Modify Tx

apomorphine + enalapril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• enalaprilat
Onapgo (apomorphine)

+

enalaprilat

1 interaction

Monitor/Modify Tx

apomorphine + enalaprilat

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• entacapone
Onapgo (apomorphine)

+

entacapone

1 interaction

Monitor/Modify Tx

apomorphine + entacapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• eplerenone
Onapgo (apomorphine)

+

eplerenone

1 interaction

Monitor/Modify Tx

apomorphine + eplerenone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• epoprostenol
Onapgo (apomorphine)

+

epoprostenol

1 interaction

Monitor/Modify Tx

apomorphine + epoprostenol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ertugliflozin
Onapgo (apomorphine)

+

ertugliflozin

1 interaction

Monitor/Modify Tx

apomorphine + ertugliflozin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• escitalopram
Onapgo (apomorphine)

+

escitalopram

1 interaction

Monitor/Modify Tx

apomorphine + escitalopram

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• esketamine
Onapgo (apomorphine)

+

esketamine

1 interaction

Monitor/Modify Tx

apomorphine + esketamine

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• esmolol
Onapgo (apomorphine)

+

esmolol

1 interaction

Monitor/Modify Tx

apomorphine + esmolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• estazolam
Onapgo (apomorphine)

+

estazolam

1 interaction

Monitor/Modify Tx

apomorphine + estazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• eszopiclone
Onapgo (apomorphine)

+

eszopiclone

1 interaction

Monitor/Modify Tx

apomorphine + eszopiclone

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ethacrynic acid
Onapgo (apomorphine)

+

ethacrynic acid

1 interaction

Monitor/Modify Tx

apomorphine + ethacrynic acid

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ethanol (in some formulations)
Onapgo (apomorphine)

+

ethanol (in some formulations)

1 interaction

Monitor/Modify Tx

apomorphine + ethanol (in some formulations)

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• etomidate
Onapgo (apomorphine)

+

etomidate

1 interaction

Monitor/Modify Tx

apomorphine + etomidate

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• felodipine
Onapgo (apomorphine)

+

felodipine

1 interaction

Monitor/Modify Tx

apomorphine + felodipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• fentanyl
Onapgo (apomorphine)

+

fentanyl

1 interaction

Monitor/Modify Tx

apomorphine + fentanyl

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• ferumoxytol
Onapgo (apomorphine)

+

ferumoxytol

1 interaction

Monitor/Modify Tx

apomorphine + ferumoxytol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• fingolimod
Onapgo (apomorphine)

+

fingolimod

1 interaction

Monitor/Modify Tx

apomorphine + fingolimod

monitor ECG overnight during fingolimod initiation/titration: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flaxseed
Onapgo (apomorphine)

+

flaxseed

1 interaction

Monitor/Modify Tx

apomorphine + flaxseed

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• flibanserin
Onapgo (apomorphine)

+

flibanserin

1 interaction

Monitor/Modify Tx

apomorphine + flibanserin

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• fluconazole
Onapgo (apomorphine)

+

fluconazole

1 interaction

Monitor/Modify Tx

apomorphine + fluconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• flurazepam
Onapgo (apomorphine)

+

flurazepam

1 interaction

Monitor/Modify Tx

apomorphine + flurazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• formoterol inhaled
Onapgo (apomorphine)

+

formoterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + formoterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• fosinopril
Onapgo (apomorphine)

+

fosinopril

1 interaction

Monitor/Modify Tx

apomorphine + fosinopril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• foslevodopa
Onapgo (apomorphine)

+

foslevodopa

1 interaction

Monitor/Modify Tx

apomorphine + foslevodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• fostemsavir
Onapgo (apomorphine)

+

fostemsavir

1 interaction

Monitor/Modify Tx

apomorphine + fostemsavir

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• furosemide
Onapgo (apomorphine)

+

furosemide

1 interaction

Monitor/Modify Tx

apomorphine + furosemide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• gabapentin
Onapgo (apomorphine)

+

gabapentin

1 interaction

Monitor/Modify Tx

apomorphine + gabapentin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• gabapentin enacarbil
Onapgo (apomorphine)

+

gabapentin enacarbil

1 interaction

Monitor/Modify Tx

apomorphine + gabapentin enacarbil

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• garlic
Onapgo (apomorphine)

+

garlic

1 interaction

Monitor/Modify Tx

apomorphine + garlic

monitor BP w/ supplemental garlic; dietary intake OK: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• gemtuzumab ozogamicin
Onapgo (apomorphine)

+

gemtuzumab ozogamicin

1 interaction

Monitor/Modify Tx

apomorphine + gemtuzumab ozogamicin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• gepirone
Onapgo (apomorphine)

+

gepirone

1 interaction

Monitor/Modify Tx

apomorphine + gepirone

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• guanfacine
Onapgo (apomorphine)

+

guanfacine

1 interaction

Monitor/Modify Tx

apomorphine + guanfacine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• hydralazine
Onapgo (apomorphine)

+

hydralazine

1 interaction

Monitor/Modify Tx

apomorphine + hydralazine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• hydrochlorothiazide
Onapgo (apomorphine)

+

hydrochlorothiazide

1 interaction

Monitor/Modify Tx

apomorphine + hydrochlorothiazide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• hydromorphone
Onapgo (apomorphine)

+

hydromorphone

1 interaction

Monitor/Modify Tx

apomorphine + hydromorphone

monitor resp. rate, BP, decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• ifosfamide
Onapgo (apomorphine)

+

ifosfamide

1 interaction

Monitor/Modify Tx

apomorphine + ifosfamide

D/C one or both drugs if encephalopathy occurs; otherwise, caution advised: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• iloprost
Onapgo (apomorphine)

+

iloprost

1 interaction

Monitor/Modify Tx

apomorphine + iloprost

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• iloprost inhaled
Onapgo (apomorphine)

+

iloprost inhaled

1 interaction

Monitor/Modify Tx

apomorphine + iloprost inhaled

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• imipramine
Onapgo (apomorphine)

+

imipramine

1 interaction

Monitor/Modify Tx

apomorphine + imipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• indapamide
Onapgo (apomorphine)

+

indapamide

1 interaction

Monitor/Modify Tx

apomorphine + indapamide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• irbesartan
Onapgo (apomorphine)

+

irbesartan

1 interaction

Monitor/Modify Tx

apomorphine + irbesartan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• iron sucrose
Onapgo (apomorphine)

+

iron sucrose

1 interaction

Monitor/Modify Tx

apomorphine + iron sucrose

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• isosorbide dinitrate
Onapgo (apomorphine)

+

isosorbide dinitrate

1 interaction

Monitor/Modify Tx

apomorphine + isosorbide dinitrate

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• isosorbide mononitrate
Onapgo (apomorphine)

+

isosorbide mononitrate

1 interaction

Monitor/Modify Tx

apomorphine + isosorbide mononitrate

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• isradipine
Onapgo (apomorphine)

+

isradipine

1 interaction

Monitor/Modify Tx

apomorphine + isradipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ketamine
Onapgo (apomorphine)

+

ketamine

1 interaction

Monitor/Modify Tx

apomorphine + ketamine

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression (incl. life-threatening), psychomotor impairment (additive effects)

• labetalol
Onapgo (apomorphine)

+

labetalol

1 interaction

Monitor/Modify Tx

apomorphine + labetalol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• landiolol
Onapgo (apomorphine)

+

landiolol

1 interaction

Monitor/Modify Tx

apomorphine + landiolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• lapatinib
Onapgo (apomorphine)

+

lapatinib

1 interaction

Monitor/Modify Tx

apomorphine + lapatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• lemborexant
Onapgo (apomorphine)

+

lemborexant

1 interaction

Monitor/Modify Tx

apomorphine + lemborexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• lenvatinib
Onapgo (apomorphine)

+

lenvatinib

1 interaction

Monitor/Modify Tx

apomorphine + lenvatinib

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levalbuterol inhaled
Onapgo (apomorphine)

+

levalbuterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + levalbuterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• levobunolol ophthalmic
Onapgo (apomorphine)

+

levobunolol ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + levobunolol ophthalmic

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• levodopa
Onapgo (apomorphine)

+

levodopa

1 interaction

Monitor/Modify Tx

apomorphine + levodopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• levorphanol
Onapgo (apomorphine)

+

levorphanol

1 interaction

Monitor/Modify Tx

apomorphine + levorphanol

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• lidocaine
Onapgo (apomorphine)

+

lidocaine

1 interaction

Monitor/Modify Tx

apomorphine + lidocaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• lisinopril
Onapgo (apomorphine)

+

lisinopril

1 interaction

Monitor/Modify Tx

apomorphine + lisinopril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• lorazepam
Onapgo (apomorphine)

+

lorazepam

1 interaction

Monitor/Modify Tx

apomorphine + lorazepam

monitor resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• losartan
Onapgo (apomorphine)

+

losartan

1 interaction

Monitor/Modify Tx

apomorphine + losartan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• lubiprostone
Onapgo (apomorphine)

+

lubiprostone

1 interaction

Monitor/Modify Tx

apomorphine + lubiprostone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• magnesium sulfate
Onapgo (apomorphine)

+

magnesium sulfate

1 interaction

Monitor/Modify Tx

apomorphine + magnesium sulfate

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• maraviroc
Onapgo (apomorphine)

+

maraviroc

1 interaction

Monitor/Modify Tx

apomorphine + maraviroc

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• mavorixafor
Onapgo (apomorphine)

+

mavorixafor

1 interaction

Monitor/Modify Tx

apomorphine + mavorixafor

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• mefloquine
Onapgo (apomorphine)

+

mefloquine

1 interaction

Monitor/Modify Tx

apomorphine + mefloquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• meperidine
Onapgo (apomorphine)

+

meperidine

1 interaction

Monitor/Modify Tx

apomorphine + meperidine

monitor resp. rate, ECG, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• mepivacaine
Onapgo (apomorphine)

+

mepivacaine

1 interaction

Monitor/Modify Tx

apomorphine + mepivacaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• methohexital
Onapgo (apomorphine)

+

methohexital

1 interaction

Monitor/Modify Tx

apomorphine + methohexital

monitor resp. rate, BP: combo may incr. risk of CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• methyldopa
Onapgo (apomorphine)

+

methyldopa

1 interaction

Monitor/Modify Tx

apomorphine + methyldopa

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• methylene blue injection
Onapgo (apomorphine)

+

methylene blue injection

1 interaction

Monitor/Modify Tx

apomorphine + methylene blue injection

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• metolazone
Onapgo (apomorphine)

+

metolazone

1 interaction

Monitor/Modify Tx

apomorphine + metolazone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• metoprolol
Onapgo (apomorphine)

+

metoprolol

1 interaction

Monitor/Modify Tx

apomorphine + metoprolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• metronidazole
Onapgo (apomorphine)

+

metronidazole

1 interaction

Monitor/Modify Tx

apomorphine + metronidazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• midostaurin
Onapgo (apomorphine)

+

midostaurin

1 interaction

Monitor/Modify Tx

apomorphine + midostaurin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• milrinone
Onapgo (apomorphine)

+

milrinone

1 interaction

Monitor/Modify Tx

apomorphine + milrinone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• minoxidil
Onapgo (apomorphine)

+

minoxidil

1 interaction

Monitor/Modify Tx

apomorphine + minoxidil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• mirtazapine
Onapgo (apomorphine)

+

mirtazapine

1 interaction

Monitor/Modify Tx

apomorphine + mirtazapine

monitor ECG, BP; consider decr. dose of one or both drugs: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• moexipril
Onapgo (apomorphine)

+

moexipril

1 interaction

Monitor/Modify Tx

apomorphine + moexipril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• morphine
Onapgo (apomorphine)

+

morphine

1 interaction

Monitor/Modify Tx

apomorphine + morphine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• nadolol
Onapgo (apomorphine)

+

nadolol

1 interaction

Monitor/Modify Tx

apomorphine + nadolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nalbuphine
Onapgo (apomorphine)

+

nalbuphine

1 interaction

Monitor/Modify Tx

apomorphine + nalbuphine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• nattokinase
Onapgo (apomorphine)

+

nattokinase

1 interaction

Monitor/Modify Tx

apomorphine + nattokinase

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• naxitamab
Onapgo (apomorphine)

+

naxitamab

1 interaction

Monitor/Modify Tx

apomorphine + naxitamab

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nebivolol
Onapgo (apomorphine)

+

nebivolol

1 interaction

Monitor/Modify Tx

apomorphine + nebivolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nelarabine
Onapgo (apomorphine)

+

nelarabine

1 interaction

Monitor/Modify Tx

apomorphine + nelarabine

withhold nelarabine if Grade 2 or greater somnolence occurs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• niacin (vitamin B3)
Onapgo (apomorphine)

+

niacin (vitamin B3)

1 interaction

Monitor/Modify Tx

apomorphine + niacin (vitamin B3)

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nicardipine
Onapgo (apomorphine)

+

nicardipine

1 interaction

Monitor/Modify Tx

apomorphine + nicardipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nifedipine
Onapgo (apomorphine)

+

nifedipine

1 interaction

Monitor/Modify Tx

apomorphine + nifedipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nimodipine
Onapgo (apomorphine)

+

nimodipine

1 interaction

Monitor/Modify Tx

apomorphine + nimodipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nisoldipine
Onapgo (apomorphine)

+

nisoldipine

1 interaction

Monitor/Modify Tx

apomorphine + nisoldipine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nitric oxide
Onapgo (apomorphine)

+

nitric oxide

1 interaction

Monitor/Modify Tx

apomorphine + nitric oxide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nitrite
Onapgo (apomorphine)

+

nitrite

1 interaction

Monitor/Modify Tx

apomorphine + nitrite

monitor BP: combo may incr. risk of severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

• nitroglycerin
Onapgo (apomorphine)

+

nitroglycerin

1 interaction

Monitor/Modify Tx

apomorphine + nitroglycerin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• nitroprusside
Onapgo (apomorphine)

+

nitroprusside

1 interaction

Monitor/Modify Tx

apomorphine + nitroprusside

monitor BP: combo may incr. risk of severe or life-threatening hypotension, incl. orthostasis, syncope (additive effects)

• nortriptyline
Onapgo (apomorphine)

+

nortriptyline

1 interaction

Monitor/Modify Tx

apomorphine + nortriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• ofloxacin
Onapgo (apomorphine)

+

ofloxacin

1 interaction

Monitor/Modify Tx

apomorphine + ofloxacin

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• olmesartan medoxomil
Onapgo (apomorphine)

+

olmesartan medoxomil

1 interaction

Monitor/Modify Tx

apomorphine + olmesartan medoxomil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• olodaterol inhaled
Onapgo (apomorphine)

+

olodaterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + olodaterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• opicapone
Onapgo (apomorphine)

+

opicapone

1 interaction

Monitor/Modify Tx

apomorphine + opicapone

monitor BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• opium
Onapgo (apomorphine)

+

opium

1 interaction

Monitor/Modify Tx

apomorphine + opium

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• osilodrostat
Onapgo (apomorphine)

+

osilodrostat

1 interaction

Monitor/Modify Tx

apomorphine + osilodrostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• oxazepam
Onapgo (apomorphine)

+

oxazepam

1 interaction

Monitor/Modify Tx

apomorphine + oxazepam

monitor resp. rate, BP: combo may incr. risk of CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• oxybutynin
Onapgo (apomorphine)

+

oxybutynin

1 interaction

Monitor/Modify Tx

apomorphine + oxybutynin

decr. dose of one or both drugs or consider oxybutynin transdermal patch: combo may incr. risk of CNS depression, psychomotor impairment; somnolence less likely w/ oxybutynin transdermal patch (additive effects)

• oxycodone
Onapgo (apomorphine)

+

oxycodone

1 interaction

Monitor/Modify Tx

apomorphine + oxycodone

monitor resp. rate, BP; decr. oxycodone start dose by at least 50%, consider decr. apomorphine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• oxymorphone
Onapgo (apomorphine)

+

oxymorphone

1 interaction

Monitor/Modify Tx

apomorphine + oxymorphone

monitor resp. rate, BP; decr. oxymorphone start dose by at least 50%, consider decr. apomorphine dose, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• palopegteriparatide
Onapgo (apomorphine)

+

palopegteriparatide

1 interaction

Monitor/Modify Tx

apomorphine + palopegteriparatide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• pentazocine
Onapgo (apomorphine)

+

pentazocine

1 interaction

Monitor/Modify Tx

apomorphine + pentazocine

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• pentobarbital
Onapgo (apomorphine)

+

pentobarbital

1 interaction

Monitor/Modify Tx

apomorphine + pentobarbital

monitor resp. rate, BP: combo may incr. risk of CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• perindopril
Onapgo (apomorphine)

+

perindopril

1 interaction

Monitor/Modify Tx

apomorphine + perindopril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• phenoxybenzamine
Onapgo (apomorphine)

+

phenoxybenzamine

1 interaction

Monitor/Modify Tx

apomorphine + phenoxybenzamine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• phentolamine
Onapgo (apomorphine)

+

phentolamine

1 interaction

Monitor/Modify Tx

apomorphine + phentolamine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• pindolol
Onapgo (apomorphine)

+

pindolol

1 interaction

Monitor/Modify Tx

apomorphine + pindolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• posaconazole
Onapgo (apomorphine)

+

posaconazole

1 interaction

Monitor/Modify Tx

apomorphine + posaconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• pralsetinib
Onapgo (apomorphine)

+

pralsetinib

1 interaction

Monitor/Modify Tx

apomorphine + pralsetinib

monitor ECG; consider monitoring electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• prazosin
Onapgo (apomorphine)

+

prazosin

1 interaction

Monitor/Modify Tx

apomorphine + prazosin

monitor BP, especially during prazosin initiation/titration: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• pregabalin
Onapgo (apomorphine)

+

pregabalin

1 interaction

Monitor/Modify Tx

apomorphine + pregabalin

monitor resp. rate: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment (additive effects)

• primaquine
Onapgo (apomorphine)

+

primaquine

1 interaction

Monitor/Modify Tx

apomorphine + primaquine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• primidone
Onapgo (apomorphine)

+

primidone

1 interaction

Monitor/Modify Tx

apomorphine + primidone

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• procarbazine
Onapgo (apomorphine)

+

procarbazine

1 interaction

Monitor/Modify Tx

apomorphine + procarbazine

monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• propofol
Onapgo (apomorphine)

+

propofol

1 interaction

Monitor/Modify Tx

apomorphine + propofol

monitor resp. rate, BP; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• propranolol
Onapgo (apomorphine)

+

propranolol

1 interaction

Monitor/Modify Tx

apomorphine + propranolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• protriptyline
Onapgo (apomorphine)

+

protriptyline

1 interaction

Monitor/Modify Tx

apomorphine + protriptyline

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• quazepam
Onapgo (apomorphine)

+

quazepam

1 interaction

Monitor/Modify Tx

apomorphine + quazepam

monitor resp. rate; consider decr. dose of one or both drugs: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• quinapril
Onapgo (apomorphine)

+

quinapril

1 interaction

Monitor/Modify Tx

apomorphine + quinapril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ramipril
Onapgo (apomorphine)

+

ramipril

1 interaction

Monitor/Modify Tx

apomorphine + ramipril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ranolazine
Onapgo (apomorphine)

+

ranolazine

1 interaction

Monitor/Modify Tx

apomorphine + ranolazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• rasagiline
Onapgo (apomorphine)

+

rasagiline

1 interaction

Monitor/Modify Tx

apomorphine + rasagiline

monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• relugolix
Onapgo (apomorphine)

+

relugolix

1 interaction

Monitor/Modify Tx

apomorphine + relugolix

if prostate cancer use, monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

• remifentanil
Onapgo (apomorphine)

+

remifentanil

1 interaction

Monitor/Modify Tx

apomorphine + remifentanil

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• remimazolam
Onapgo (apomorphine)

+

remimazolam

1 interaction

Monitor/Modify Tx

apomorphine + remimazolam

monitor BP, resp. rate; use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), profound CNS and resp. depression, psychomotor impairment (additive effects)

• riociguat
Onapgo (apomorphine)

+

riociguat

1 interaction

Monitor/Modify Tx

apomorphine + riociguat

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• ropivacaine
Onapgo (apomorphine)

+

ropivacaine

1 interaction

Monitor/Modify Tx

apomorphine + ropivacaine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• sacituzumab govitecan
Onapgo (apomorphine)

+

sacituzumab govitecan

1 interaction

Monitor/Modify Tx

apomorphine + sacituzumab govitecan

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• sacubitril
Onapgo (apomorphine)

+

sacubitril

1 interaction

Monitor/Modify Tx

apomorphine + sacubitril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• safinamide
Onapgo (apomorphine)

+

safinamide

1 interaction

Monitor/Modify Tx

apomorphine + safinamide

monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• salmeterol inhaled
Onapgo (apomorphine)

+

salmeterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + salmeterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• selegiline
Onapgo (apomorphine)

+

selegiline

1 interaction

Monitor/Modify Tx

apomorphine + selegiline

monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• selegiline transdermal
Onapgo (apomorphine)

+

selegiline transdermal

1 interaction

Monitor/Modify Tx

apomorphine + selegiline transdermal

monitor BP: combo may incr. risk of severe hypotension (incl. orthostasis, syncope), CNS depression, psychomotor impairment (additive effects)

• sildenafil
Onapgo (apomorphine)

+

sildenafil

1 interaction

Monitor/Modify Tx

apomorphine + sildenafil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• silodosin
Onapgo (apomorphine)

+

silodosin

1 interaction

Monitor/Modify Tx

apomorphine + silodosin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• sodium ferric gluconate complex
Onapgo (apomorphine)

+

sodium ferric gluconate complex

1 interaction

Monitor/Modify Tx

apomorphine + sodium ferric gluconate complex

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• sotagliflozin
Onapgo (apomorphine)

+

sotagliflozin

1 interaction

Monitor/Modify Tx

apomorphine + sotagliflozin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• sparsentan
Onapgo (apomorphine)

+

sparsentan

1 interaction

Monitor/Modify Tx

apomorphine + sparsentan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• spironolactone
Onapgo (apomorphine)

+

spironolactone

1 interaction

Monitor/Modify Tx

apomorphine + spironolactone

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• sufentanil
Onapgo (apomorphine)

+

sufentanil

1 interaction

Monitor/Modify Tx

apomorphine + sufentanil

monitor resp. rate, BP; decr. sufentanil start dose, consider decr. apomorphine dose, use lowest effective doses: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• sunitinib
Onapgo (apomorphine)

+

sunitinib

1 interaction

Monitor/Modify Tx

apomorphine + sunitinib

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• suvorexant
Onapgo (apomorphine)

+

suvorexant

1 interaction

Monitor/Modify Tx

apomorphine + suvorexant

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• tacrolimus
Onapgo (apomorphine)

+

tacrolimus

1 interaction

Monitor/Modify Tx

apomorphine + tacrolimus

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• tadalafil
Onapgo (apomorphine)

+

tadalafil

1 interaction

Monitor/Modify Tx

apomorphine + tadalafil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• tagraxofusp
Onapgo (apomorphine)

+

tagraxofusp

1 interaction

Monitor/Modify Tx

apomorphine + tagraxofusp

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• tamsulosin
Onapgo (apomorphine)

+

tamsulosin

1 interaction

Monitor/Modify Tx

apomorphine + tamsulosin

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• tapentadol
Onapgo (apomorphine)

+

tapentadol

1 interaction

Monitor/Modify Tx

apomorphine + tapentadol

monitor resp. rate, BP; decr. dose of one or both drugs, use lowest effective doses and shortest duration of concomitant tx: combo may incr. risk of profound CNS and resp. depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• taurine
Onapgo (apomorphine)

+

taurine

1 interaction

Monitor/Modify Tx

apomorphine + taurine

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• tazemetostat
Onapgo (apomorphine)

+

tazemetostat

1 interaction

Monitor/Modify Tx

apomorphine + tazemetostat

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• telmisartan
Onapgo (apomorphine)

+

telmisartan

1 interaction

Monitor/Modify Tx

apomorphine + telmisartan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• temazepam
Onapgo (apomorphine)

+

temazepam

1 interaction

Monitor/Modify Tx

apomorphine + temazepam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• terazosin
Onapgo (apomorphine)

+

terazosin

1 interaction

Monitor/Modify Tx

apomorphine + terazosin

monitor BP, especially during terazosin initiation/titration: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• terbutaline
Onapgo (apomorphine)

+

terbutaline

1 interaction

Monitor/Modify Tx

apomorphine + terbutaline

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• timolol
Onapgo (apomorphine)

+

timolol

1 interaction

Monitor/Modify Tx

apomorphine + timolol

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• timolol ophthalmic
Onapgo (apomorphine)

+

timolol ophthalmic

1 interaction

Monitor/Modify Tx

apomorphine + timolol ophthalmic

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• tizanidine
Onapgo (apomorphine)

+

tizanidine

1 interaction

Monitor/Modify Tx

apomorphine + tizanidine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• tolcapone
Onapgo (apomorphine)

+

tolcapone

1 interaction

Monitor/Modify Tx

apomorphine + tolcapone

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• tolterodine
Onapgo (apomorphine)

+

tolterodine

1 interaction

Monitor/Modify Tx

apomorphine + tolterodine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• torsemide
Onapgo (apomorphine)

+

torsemide

1 interaction

Monitor/Modify Tx

apomorphine + torsemide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• trandolapril
Onapgo (apomorphine)

+

trandolapril

1 interaction

Monitor/Modify Tx

apomorphine + trandolapril

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• treprostinil
Onapgo (apomorphine)

+

treprostinil

1 interaction

Monitor/Modify Tx

apomorphine + treprostinil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• triamterene
Onapgo (apomorphine)

+

triamterene

1 interaction

Monitor/Modify Tx

apomorphine + triamterene

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• triazolam
Onapgo (apomorphine)

+

triazolam

1 interaction

Monitor/Modify Tx

apomorphine + triazolam

monitor resp. rate: combo may incr. risk of CNS and resp. depression, psychomotor impairment (additive effects)

• trimipramine
Onapgo (apomorphine)

+

trimipramine

1 interaction

Monitor/Modify Tx

apomorphine + trimipramine

monitor BP: combo may incr. risk of CNS depression, psychomotor impairment, severe hypotension, incl. orthostasis, syncope (additive effects)

• valbenazine
Onapgo (apomorphine)

+

valbenazine

1 interaction

Monitor/Modify Tx

apomorphine + valbenazine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• valsartan
Onapgo (apomorphine)

+

valsartan

1 interaction

Monitor/Modify Tx

apomorphine + valsartan

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• vardenafil
Onapgo (apomorphine)

+

vardenafil

1 interaction

Monitor/Modify Tx

apomorphine + vardenafil

monitor ECG, BP: combo may incr. risk of QT prolongation, cardiac arrhythmias, severe hypotension, incl. orthostasis, syncope (additive effects)

• venlafaxine
Onapgo (apomorphine)

+

venlafaxine

1 interaction

Monitor/Modify Tx

apomorphine + venlafaxine

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias, CNS depression, psychomotor impairment (additive effects)

• verapamil
Onapgo (apomorphine)

+

verapamil

1 interaction

Monitor/Modify Tx

apomorphine + verapamil

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• vilanterol inhaled
Onapgo (apomorphine)

+

vilanterol inhaled

1 interaction

Monitor/Modify Tx

apomorphine + vilanterol inhaled

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voclosporin
Onapgo (apomorphine)

+

voclosporin

1 interaction

Monitor/Modify Tx

apomorphine + voclosporin

monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• voriconazole
Onapgo (apomorphine)

+

voriconazole

1 interaction

Monitor/Modify Tx

apomorphine + voriconazole

monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

• vosoritide
Onapgo (apomorphine)

+

vosoritide

1 interaction

Monitor/Modify Tx

apomorphine + vosoritide

monitor BP: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• yohimbe
Onapgo (apomorphine)

+

yohimbe

1 interaction

Monitor/Modify Tx

apomorphine + yohimbe

monitor BP, especially w/ high yohimbe doses: combo may incr. risk of severe hypotension, incl. orthostasis, syncope (additive effects)

• zaleplon
Onapgo (apomorphine)

+

zaleplon

1 interaction

Monitor/Modify Tx

apomorphine + zaleplon

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• ziconotide
Onapgo (apomorphine)

+

ziconotide

1 interaction

Monitor/Modify Tx

apomorphine + ziconotide

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)

• zolpidem
Onapgo (apomorphine)

+

zolpidem

1 interaction

Monitor/Modify Tx

apomorphine + zolpidem

consider decr. dose of one or both drugs: combo may incr. risk of CNS depression, psychomotor impairment (additive effects)